{"id":"W4385476260","doi":"10.1182/bloodadvances.2023010334","title":"Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; National Cancer Institute; Merck Sharp and Dohme; Celgene; MorphoSys; Innovent Biologics; Regeneron Pharmaceuticals; Seagen; Pfizer; Hexal AG; Genentech; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Cohort; Internal medicine; Refractory (planetary science); Brentuximab vedotin; Lymphoma; Confidence interval; Progression-free survival; Gastroenterology; Surgery; Oncology; Overall survival; Hodgkin lymphoma; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00253119,0.0005393372,0.0009150011,0.0001974147,0.0002014795,0.0007745458,0.0004038673,0.0005363935,0.0009297003],"category_scores_gemma":[0.0009993436,0.0001888832,0.001034825,0.0002106441,0.000203958,0.0003712852,0.0003157275,0.0008848158,0.0001997809],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006735364,"about_ca_system_score_gemma":0.0005946723,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008189505,"about_ca_topic_score_gemma":0.002844692,"domain_scores_codex":[0.9996217,0.0002047746,0.00001994436,0.00005086196,0.00004678229,0.00005585944],"domain_scores_gemma":[0.9993832,0.0001236099,0.0001529045,0.00004862176,0.00004867284,0.0002429572],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5929574,0.007089052,0.1174615,0.002309952,0.00942182,0.0005931907,0.0003557583,0.00550332,0.0241902,0.0005940109,0.01592345,0.2236004],"study_design_scores_gemma":[0.2881536,0.180442,0.4874271,0.0005124492,0.009230882,0.001238939,0.0001674253,0.005735975,0.00417308,0.0005734107,0.02222889,0.0001162762],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867823,0.009871197,0.0002335957,0.0002747455,0.00009639766,0.0002488419,0.001309638,0.00002959609,0.001153704],"genre_scores_gemma":[0.9914163,0.002573614,0.0003525601,0.000774682,0.0001477456,0.0002214792,0.003892934,0.0000116023,0.0006091504],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00253119,"threshold_uncertainty_score":0.01338637,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02890083118372735,"score_gpt":0.3261303128704693,"score_spread":0.297229481686742,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}